Axial Biotech Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Axial Biotech Inc.
With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.
Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.
This week's roundup includes Almirall's appointment of a former Sanofi employee as CEO and various other high-level appointments by Axial, Therachon, Theranexus and Karolinska.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.